Reaction

Gastrointestinal Ulcer reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,194 reports · 53 co-occurring drugs

As of the last recalculation, Gastrointestinal Ulcer appears in 2,194 FAERS reports alongside 53 co-occurring drug terms. The strongest observed disproportionality signal is GANCICLOVIR SODIUM (PRR 13.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ganciclovir Sodium	15	13.5	13.6
Ganciclovir	14	13.1	13.1
Valganciclovir Hydrochloride Powder,	15	11.7	11.8
Sucralfate	24	9.6	9.6
Valganciclovir	18	9.1	9.1
Valganciclovir Hydrochloride	18	9.1	9.1
Thiamine Hydrochloride, Riboflavin 5 Phosphate Sodium, Dexpanthenol And Niacinamide	28	8.9	8.9
Sorafenib	19	8.7	8.8
Fondaparinux Sodium	7	8.2	8.2
Azathioprine	71	7.9	7.9
Ciprofloxacin Hydrochloride And Hydrocortisone	17	7.8	7.8
Sucralfate Oral	11	7.4	7.4
Ursosiol	15	7.4	7.4
Sucralfate Oral Suspension	11	7.3	7.4
Diclofenac	62	7.0	7.0
Isosorbide Mononitrate	15	6.9	6.9
Naproxen Sodium	97	6.7	6.7
Cefepime	10	6.6	6.6
Ursodiol	15	6.6	6.6
Niacin	8	6.6	6.6
Naproxen Sodium Tablet	36	6.5	6.5
Mycophenilic Acid	14	6.4	6.4
Diclofenac Sodium 1%	24	6.4	6.4
Diclofenac Sodium Topical	24	6.4	6.4
Diclofenac Sodium Topical Gel, 1%	24	6.4	6.4
Sirolimus	9	6.4	6.4
Cefepime Hydrochloride	10	5.9	5.9
Prasugrel Hydrochloride	6	5.6	5.6
Vedolizumab	50	5.6	5.6
Oxaliplatin	42	5.5	5.5
Acetaminophen, Aspirin, And Caffeine	12	5.4	5.4
Ticagrelor	18	5.4	5.4
Erlotinib Hydrochloride	7	5.3	5.3
Gefitinib	5	5.3	5.3
Posaconazole Delayed-Release	6	5.2	5.2
Encorafenib	5	4.8	4.8
Pitavastatin Calcium	5	4.6	4.6
Gemcitabine Hydrochloride	25	4.5	4.5
Acetaminophen, Aspirin (Nsaid) And Caffeine	8	4.5	4.5
Cetuximab	14	4.3	4.3
Eptinezumab-Jjmr	4	4.2	4.2
Agalsidase Beta	4	4.1	4.1
Erlotinib	4	3.9	3.9
Ruxolitinib	28	3.7	3.7
Diclofenac Potassium	4	3.5	3.5
Atezolizumab	14	3.4	3.4
Diclofenac Potassium, Film Coated	3	3.4	3.4
Diclofenac Potassium Tablets	3	3.4	3.4
Dabigatran Etexilate	26	3.2	3.2
Diroximel Fumarate	4	3.2	3.2
Dabigatran Etexilate Mesylate	22	2.9	2.9
Sarilumab	5	1.8	1.8
Valbenazine	3	1.1	1.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.